Key Benefits
• Prevents dental caries in children• Inhibits dual-species biofilm of S. mutans and C. albicans• Reduces oral pathogens and freshens breath• Modulates oral microbiota balance
Human Clinical Data
• Randomized, double‑blind, placebo‑controlled trial in 108 children (3‑6 yrs) with early childhood caries (ECC)• Recommended dose: 16 billion CFU/dose, twice daily for 4 weeks• Significant reduction in salivary S. mutans and C. albicans counts (p < 0.01)• Mean reductions (log copies/ng DNA) at day 28: 0.12 and 0.11, respectively; placebo showed almost no change• Trial registered at ChiCTR2100047849, approved by Wuxi Children's Hospital Ethics Committee
Mechanism
Disrupts biofilm formation and destroys mature biofilms; reduces water‑insoluble exopolysaccharide production; visibly loosens biofilm structure and eliminates hyphae of C. albicans
Patent
National Invention Patent – Method for inhibiting dual-species biofilm of S. mutans and C. albicans; A Lactobacillus plantarum strain for preventing and treating dental caries
Commercial Use
Already used in multiple products, including children’s probiotics and oral‑health formulas
Why Choose CCFM8724?
Only strain in our portfolio with pediatric clinical trial data – a strong regulatory and marketing advantage for children's products
Mechanistically validated against both bacterial and fungal oral pathogens – broader spectrum than typical anti‑caries probiotics
Ideal for functional candies, chewing tablets, and powdered supplements targeting oral hygiene and overall upper respiratory/digestive tract wellness